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ABSRTACT 
Mitochondria are the most vital organelle in the cell because of its multitask properties. They are well known for the production of energy in the 
form of adenosine triphosphate (ATP) through oxidative phosphorylation (OXPHOS), which involves multiple complexes and cofactors. 
Mitochondria in addition to ATP production, also perform other vital functions like generation of reactive oxygen species (ROS), antioxidants, 
apoptosis, signaling and hormone actions. 
Because of their multiple actions, it is quite expected that their dysfunction will result in the number of effects. Since most vital organs exclusively 
depend on ATP to perform their functions, therefore impediment in its supply resulting from mitochondrial dysfunction will be detrimental and 
have a widespread spectrum. Neurodegenerative disorders, Huntington’s disease, cardiovascular disease (CVD), epilepsy, aging, metabolic 
syndrome, diabetes, autism, muscular atrophy, lou gehrig’s disease, neoplasia, down syndrome are few instances where mitochondrial dysfunction 
is the basic cause in pathogenesis.  
Mitochondrial disorders are either Primary or secondary disorders. Primary mitochondrial disease or disorder (PMD) has mitochondrial or nuclear 
deoxyribonucleic acid (mt DNA or nDNA) mutation affecting oxidative phosphorylation (OXPHOS). While Secondary mitochondrial dysfunction 
(SMD) does not involve OXPHOS but is the result of mutations in non OXPHOS genes. Secondary mitochondrial dysfunction (SMD) can also be 
acquired secondary to adverse factors those cause oxidative stress. 
All this highlights the role of mitochondria and makes it a new therapeutic target in managing these disorders. The present review has briefly 
discussed the secondary mitochondrial dysfunctional disorders and the approach to tackle it. 
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INTRODUCTION 
Dysfunctions of mitochondria are of immense clinical importance as 
the major energy needs of the body are met by mitochondria. Lack of 
energy due to dysfunction of the mitochondrial respiratory chain 
produces wide spectrum of clinical presentations ranging from rare 
childhood genetic diseases to old age neurodegenerative disorders. 
They can be caused by mutation of genes encoded by either nuclear 
DNA (nDNA). or mitochondrial DNA (mtDNA). Though any organ can 
get affected but high energy demand organs like the brain, heart, 
eyes, muscles, gastrointestinal tract suffer the most and produce 
varied clinical symptoms [1]. 
Basic mitochondrial functions 
Mitochondria generates adenosine triphosphate (ATP) by oxidative 
phosphorylation (OXPHOS) via the electron transport chain (ETC). 
Five enzyme complexes (Complexes I–V) and two transporters 
(ubiquinone and cytochrome c) participate in the process of ATP 
generation, wherein electrons are moved down the chain. The five 
complexes in OXPHOS include complex I (NADH: ubiquinoneoxido 
reductase), complex II (succinate dehydrogenase), complex III (CoQ-
cytochrome c reductase), complex IV (cytochrome c oxidase), and 
complex V (ATP synthase).  
In addition to ATP generation, the mitochondria produce reactive 
oxidative species (ROS) which are implicated in oxidative stress 
disease states. Recently ROS are shown to play a significant role in 
physiological signaling, maintenance of vascular tone, and oxygen 
sensing. The levels of ROS and the site at which ROS are generated is 
important. Low levels of ROS are beneficial and facilitate adaptation 
to stress via signaling, while on the other hand, high levels of ROS 
are detrimental and trigger oxidative stress. Receptors for steroid 
hormones, glucocorticoids, estrogens, and triiodothyronine, have 
been identified in mitochondria. Mitochondria primarily regulate 
energy production and apoptosis and these actions are modulated, 
in turn, by steroid and thyroid hormones in the course of 
their actions on metabolism, growth and development [2]. 
Mitochondria triggers cell death pathways necrosis when ATP levels 
fall below a certain threshold and apoptosis through the release of 
mitochondrial cytochrome c into the cytoplasm [3]. The 
mitochondrion also has a mechanism to protect against ROS damage 
via antioxidants (e. g., superoxide dismutase, glutathione, thioredoxin), 
but their ability to protect gets upset when a large amount of ROS are 
produced in pathological states. Normally, mitochondria displays a 
balance between the antioxidant actions and oxidative stress but this 
gets disturbed towards latter during its dysfunction. Oxidative stress is 
contributed by the increased opening of mitochondrial permeability 
transition pore (mPTP) channels, stimulation of NADPH oxidase 
2 (Nox2) and Nox4 (NADPH oxidase family), improper expression of 
mitochondrial and nuclear proteins, mitochondrial deoxyribonucleic 
acid (mtDNA) damage and fragmentation and ageing, while 
antioxidant actions are contributed by selective down-regulation of 
ETC complexes, blockage of mPTP channels, stimulation of mitophagy, 
expression of mitochondrial catalases, superoxide dismutase [4]. 
Reactive Oxygen Species (ROS) cause oxidative damage and is 
thought to be the main cause of aging and age-related diseases, 
including cancer, diabetes and Parkinson's disease. The 
mitochondria from old individuals have higher levels of ROS. 
However, interestingly the ROS not only causes oxidative stress but 
has recently also shown to participate in cellular signaling in many 
physiological processes and may be beneficial.  
Reverse electron transport (RET) process also produces a significant 
amount of ROS. Reverse electron transport happens when electrons 
from ubiquinol are transferred back to respiratory complex I, 
reducing NAD+to NADH. RET is found to prolong the life span of 
Drosophila in animal studies [5]. 
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Mitochondria unlike other cellular organelles, have their own DNA 
known as mitochondrial DNA, (mtDNA), which is distinct from the 
nuclear DNA (nDNA). Mitochondrial DNA (mtDNA) is more 
susceptible to mutations, which can be either wild type, a mutant 
type (homoplasmy) or both (heteroplasmy). mtDNA is maternally 
inherited because no mtDNA from the sperm enters the ovum during 
fertilization and even if it enters, ovum degrades it. Mutations will 
result in mitochondrial diseases due to lack of adequate ATP 
production and accumulation of toxic free radicals.  
Mitochondrial disorders 
Mitochondrial diseases are as such clinically heterogeneous group of 
disorders resulting from either inherited or spontaneous mutations 
in mtDNA or nDNA which lead to deleterious functions of the 
mitochondria. 
Inheritance of mitochondrial disorders can be nuclear (autosomal-
dominant (AD), autosomal recessive (AR), X-linked) or mtDNA 
(mitochondrial). Mitochondria have their own mtDNA and its mutations 
is inherited from the mother only and each child in the family inherits a 
mitochondrial disease. However, variable presentations within the same 
family can be due to heteroplasmy or within the same individual as he 
grows from infancy to adulthood because of shift in the number of 
mutant mtDNA in daughter cells due to mitotic segregation [4]. 
Types of mitochondrial disorders 
Mitochondrial diseases are Primary or genetic and secondary or 
acquired degenerative disorders. Primary mitochondrial disease 
(PMD has mitochondrial or nuclear DNA mutation affecting EXPHOS 
functioning while Secondary mitochondrial dysfunction (SMD) does 
not involve OXPHOS but can be caused in mutations in non OXPHOS 
genes. Secondary mitochondrial dysfunction (SMD) can also be 
acquired secondary to adverse factors that cause oxidative stress. 
Secondary mitochondrial dysfunctional disorders  
Mitochondrial toxins (cigarette smoke, asbestos, metals), drugs 
(Tetracycline, valproate), ischemia, infections, inflammation and 
aging. All these events leads to oxidative stress, which can ultimately 
cause mitochondrial dysfunction [6, 7]. Therefore, SMD can be 
inherited or acquired and is in contrast to PMD, which can only be 
inherited. Various conditions associated with secondary 
mitochondrial dysfunction are aging, Parkinson's disease, 
Alzheimer’s disease, autism, Huntington’s disease, amyotrophic 
lateral sclerosis, friededreich’s ataxia, schizophrenia, sepsis, 
cardiovascular diseases, cancer, diabetes and metabolic syndrome. 
Fatigue and aging 
Mitochondial dysfunction correlate with excessive fatigue and aging. 
Though, mild fatigue is multifactorial due to the number of psychological 
disorders, but moderate to severe and chronic fatigue involve 
mitochondrial dysfunction reducing ATP synthesis. In chronic fatigue 
syndrome there is oxidative damage to DNA and lipids [8, 9] and 
elevated peroxynitrite due to excessive nitric oxide, which can also result 
in lipid peroxidation and loss of mitochondrial dysfunction. Cytokine also 
exert positive feedback on nitric oxide levels [10] 
As age progresses, there is an increase in the generation of ROS and 
oxidative stress and damage to mitochondrial membranes and 
causing dysfunction. Aging is the greatest risk factor for 
degenerative diseases. It is well known that age-dependent 
accumulation of mtDNA mutations correlates with declines in 
mitochondrial function. The damaged mitochondria produce ROS 
that causes oxidative damage to various components and plays a 
major role in cell death, which affects life span. 
Sepsis 
Mitochondrial dysfunction in sepsis may be attributed to hypoxia. 
Lower perfusion induced hypoxia in sepsis augments free radical 
production because of limited oxygen and incomplete OXPHOS. On 
the other hand, molecules in the antioxidant system are also 
impaired. Mitochondria dysfunction in sepsis lead to the electron 
transport chain dysfunction results in high ROS production within 
mitochondria, that damages mitochondria membrane, ETC activity 
and mtDNA. Mitochondrial membrane permeability transition 
results in the release of cytochrome c into the cytosol that aid 
apoptosis. Increased permeability makes the Ca2+
Metabolic syndrome 
reflux into 
cytoplasm and a consequent disturbance that further activate 
related signaling pathways. Mitochondrial ROS can also transport to 
cytoplasm and induce oxidative stress, followed by oxidative stress 
signaling pathways activation, which modulate various cellular 
functions. ROS released into extracellular space will further take 
harm to other cells and organs [10, 11]. 
Metabolic syndrome (MetS) is characterized by abdominal obesity 
(physical inactivity, high waist circumference, high waist-hip ratio 
and high BMI), dyslipidemia, impaired glucose tolerance, insulin 
resistance and hypertension in a single patient.  
Oxidative stress is a well-known cause of lifestyle-related diseases. 
There is considerable evidence that oxidative stress is a key factor in 
the pathogenesis of diabetes where oxidation exceeds the protective 
antioxidant mechanism. ROS are highly reactive molecules and 
damage carbohydrates, nucleic acids, lipids and proteins. Lipid 
peroxidation plays an important role in diabetic complications [12]. 
Genetic and environmental factors, including aging, obesity, lack of 
exercise and stress, contribute to insulin resistance as a result of 
mitochondrial dysfunction. The activity or genetic variations of PGC-
1α (PPAR gamma-1 alpha) may contribute to individual variations in 
mitochondrial function and insulin resistance or diabetes.  
Mitochondrial damage causes the impairment of glucose metabolism 
and glucose uptake by cells. Type 2 diabetic patients show insulin 
resistance and reduced mitochondrial OXPHOS activity up to 40%. 
Multiple mechanisms are implicated in the causation of Diabetes 
such as less physical activity, obesity, elevated free fatty acids, 
genetic factors, oxidative stress and mitochondrial dysfunction [13, 
14]. Impaired mitochondrial function cause alteration in glucose and 
fatty acid metabolism, lower ATP production in muscle cells, 
decrease insulin secretion from β-cells and stimulation of ROS 
production [13, 14]. Alterations in lipid metabolism and the 
impairment of oxidative phosphorylation increase the accumulation 
of diacylglycerols and ceramides that block insulin secretion and 
contribute to metabolic syndrome and diabetes [16] 
Excessive free fatty acids results in decreased oxygen utilization by 
mitochondria and uncoupling of ETC systems., In addition, the 
mtDNA mutations in mitochondrial dysfunction decrease 
mitochondrial proteins and mitochondrial density [17] and impaired 
mitochondrial proteins also activates stress-related 
serine/threonine kinases that further block glucose transport and 
favour the formation of fatty acids. The excessive lipid levels also 
target the insulin receptor substrate (IRS 1-2) and Akt pathways and 
contribute to insulin resistance [19] Mitochondrial dysfunction and 
insulin resistance are linked to altered gene expression of PCG1 in 
muscle and liver tissues, downregulation of PGC1a leads to impaired 
mitochondrial biogenesis and insulin resistance [20]. 
In diabetes large amounts of glucose leads to a shift towards the 
pentose monophosphate shunt and hexosaminidase pathway, which 
result in harmful events. In pentose monophosphate shunt, the 
NADPH produced is utilized by mitochondrial oxidase (NOX) to 
produce ROS [21]. 
Neurodegenerative disorders  
Neurodegenerative diseases are a large heterogeneous group of 
disabling disorders characterized by progressive and selective loss 
of neuronal cells. 
Mitochondrion plays vital part in neuronal survival, aging and 
neurodegeneration. The accumulation of damaged mitochondria has 
been associated with aging and multiple age-related disorders, 
including Alzheimer’s disease (AD). Mitophagy is an utmost 
requirement for the degradation and removal of damaged 
mitochondria where the target mitochondria are identified by the 
autophagosomes and delivered to the lysosome for degradation. 
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Mitophagy plays important roles in mitochondrial homeostasis, 
neuroprotection, and resistance to neurodegenaration [22] 
There is ample evidence that impaired mitochondrial plays a role in 
pathogenesis of neurodegenaration. Increased mitochondrial ROS 
will result in detrimental cellular consequences to deoxyribonucleic 
acid, proteins, lipids, and decreased effectiveness of cellular 
mechanisms, initiation of inflammatory pathways, excitotoxicity, 
protein agglomeration and apoptosis. Therefore the alterations in 
apoptotic signaling may be a therapeutic strategy to cure these 
disorders. 
Alzheimer's disease (AD) is characterized by the presence of 
amyloid beta (Aβ) plaque and neurofibrillary tangles in the brain. Aβ 
impairs the OXPHOS complex IV in the inter-membrane space of 
mitochondria to produce ROS and results in the inhibition of Aβ-
binding alcohol dehydrogenase (ABAD), which causes mitochondrial 
stress and apoptosis. 
AD involves mitochondrial dysfunction, bioenergetic deficit, and 
altered mitophagy. The autophagy/lysosome pathway that removes 
damaged mitochondria (mitophagy) is compromised in AD. 
Accumulation of dysfunctional mitochondria contributes to synaptic 
dysfunction and cognitive deficits by triggering Aβ and Tau 
accumulation through increases in oxidative damage and cellular 
energy deficits [22]. Dysfunctional mitochondria accumulate due to 
the impaired mitophagy, which can induce inflammation and 
inadequate mitochondrial biogenesis.  
Parkinson’s disease (PD) is a common neurodegenerative disorder 
characterized by dopamine depletion in the striatum. PD is 
characterized by bradykinesia, tremor, rigidity, and weakening of 
postural reflexes. It has varied aetiology. However, enormous 
evidence suggests that mitochondrial dysfunction plays an essential 
role. The mutations or polymorphisms in mtDNA and nDNA-encoded 
genes have been identified as Parkinson’s disease-linked genes, 
although these mutations are rare. α-synuclein (α-Syn), parkin/DJ-1, 
phosphatase tensin homologue (PTEN)-induced kinase 1 (PINK1) 
and leucine-rich-repeat kinase 2 (LRRK2)ATP13A2, 
VPS35 and CHCHD2 genes mutations are directly linked to 
mitochondrial dysfunction and oxidative stress [23, 24]. 
Huntington’s disease (HD), is a neurodegenerative disease, incurable 
disease manifested by involuntary motor impairment and cognitive 
decline associated with the preferential loss of striatal medium spiny 
neurons and is caused by mutant huntingtin (HTT) gene.  
The mutant huntingtin contains an abnormally expanded 
polyglutamine domain in striatal GABAergic neurons and impairs 
mitochondrial functions and calcium homeostasis resulting in early 
degeneration and atrophy. Two main transcription factors, p53 and 
peroxisome proliferator co-activator PGC-1α, have been implicated 
in HD for their roles in regulating mitochondrial function, low ATP, 
high ROS levels and apoptosis [25].  
Lou Gehrig’s disease: Mitochondrial dysfunctions have a crucial role 
in the pathogenesis of amyotrophic lateral sclerosis (Lou Gehrig’s 
disease) where both upper and lower motor neurons are affected. 
This disorder is familial in 10% of cases where mutations in the gene 
encoding Cu/Zn superoxide dismutase 1 (SOD1) is responsible. It is 
suggested that impaired mitochondrial trafficking through Miro1 
deficiency specifically causes motor neuron degeneration and also 
decreased activities of oxidative phosphorylation (OXPHOS) 
complexes I+III, II+III, IV, and citrate synthase [26]. 
Cardiovascular diseases 
Mitochondrial dysfunction is associated with the development of 
numerous cardiac diseases such as atherosclerosis, ischemia-
reperfusion (I/R) injury, hypertension, cardiac hypertrophy and 
heart failure (HF), due to the uncontrolled production of reactive 
oxygen species (ROS). Reactive oxygen species (ROS) including the 
superoxide anion, the hydroxyl radical, and hydrogen peroxide are 
well known for their deleterious effects, but are also critical 
signaling molecules with important roles in cardiac physiology as 
cardiac ROS regulates heart development and cardiomyocyte 
maturation, cardiac calcium handling, excitation-contraction 
coupling, and vascular tone [27]. 
Cytosolic amount of ROS is contributed by NADPH oxidases (NOX), 
xanthine oxidase, cyclooxygenases, and cytochrome P450 enzymes, 
while mitochondrial-derived respiratory chain, monoamine oxidases 
(MAOs), p66shc, and NOX4, contribute to the intracellular ROS pool. 
NOX4 localizes to mitochondria and provokes the opening of mPTP 
channel. The increased unregulated ROS levels in disease cause 
damage to DNA, proteins, lipids, and activation of mitochondrial-
permeability transition pore (mPTP), mitochondrial dysfunction, 
and cell death  
Cardiac cell pathology 
Cardiac cells have increased energy demand and mitochondrial beta-
oxidation is the main source of energy for the heart. Therefore 
mitochondria are highly concentrated in them and are responsible 
for the production of approximately 6 kg of ATP via OXPHOS [28]. 
Thus increased uncontrolled production of ROS with resultant 
mitochondrial dysfunction and changes of cellular lipids, proteins, 
enzymes and DNA forms the pathophysiologic basis for the 
development of several cardiac diseases and deprive energy to 
cardiac cell [29]. Consequently, the states like cardiac hypertrophy, 
heart failure (HF), cardiac ischemia-reperfusion injury (IRI), and 
diabetic cardiomyopathy have been found to be associated with 
mitochondrial dysfunction 
ROS induce damage in mitochondrial DNA, decrease expression of 
mitochondrial DNA repair enzymes, COUP-TFII transcription factor 
[30]. All these are an important underlying cause in various cardiac 
disorders  
Aged cardiomyocytes also contribute changes in mitochondria to 
accelerate the ROS formation as they impair mitochondrial 
biogenesis reduced gene expression of molecules implicated in fatty 
acid oxidation and Krebs cycle [31] and ROS further enhance the 
ageing process. Excessive ROS production and impaired function of 
the anti-oxidant systems are associated with the development of 
cardiac hypertrophy, remodeling and Heart failure [32]. 
Several mediators are implicated in HF such as angiotensin-II, 
norepinephrine, β-adrenergic agonists, TNF-α, endothelin-I as well 
as mechanical forces which activate PKC, MAPK, PI3K, JNK and 
nuclear factor kappa beta (NF-κB) [33]. 
The excessive ROS increase the formation of peroxynitrite which 
impairs endothelial nitric oxide (NO) synthase and NO mediated 
dilatation [34]. ROS inhibits smooth muscle cell relaxation of the 
perivascular adipose tissue and induce the formation of endothelial 
extracellular vesicles, which contain the proteins parkin and MFR1. 
Therefore, mitochondrial ROS are linked to endothelial dysfunction 
and their targeting improves endothelial function [35]. 
Atherosclerosis is a chronic inflammatory process and the most 
common factor for coronary artery disease (CAD). Atherosclerosis 
involves progressive narrowing and degeneration of arteries. The 
oxidative modification of low-density lipoproteins (LDL) in the 
arterial wall by reactive oxygen species and elevated levels of 
homocysteine in blood plasma are the key risk factors for 
atherosclerosis [36]. 
Excessive ROS in mitochondrial dysfunction oxidize cellular 
proteins, lipids and DNA, especially mtDNA, which is more prone to 
oxidative damage as it lacks histones and has minimum ability to 
repair; furthermore, mtDNA mutations trigger the induction of a 
vicious cycle of ROS. 
Oxidized LDL molecules are taken up by macrophages to form foam 
cells which are rich in lipids and cell debris. Foam cells release a 
number of pro-inflammatory mediators such as adhesion molecules 
and circulating cytokines, which attract inflammatory cells to the 
damaged vascular wall. These cytokines stimulate the formation of 
neo-intima through hyperplasia, migration and proliferation of 
vascular smooth muscle cells [37]. Cardiac ischemia cause hypoxia in 
cardiac cells that deteriorate the function of mitochondrial 
respiratory chain enzymes as a result, superoxide, hydrogen 
peroxide, peroxynitrite and hydroxyl radical are formed. The 
excessive ROS produced during ischemia and reperfusion injury has 
detrimental effects as it leads to apoptosis of endothelial cells [38]. 
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Hypertension 
Hypertension has important role in development of coronary artery 
disease (CAD). RAS plays a vital role in causation of hypertension. 
Angiotensin-II stimulates NADPH oxidase and acceleration of 
oxidative stress. Hypertension in elderly patients is associated with 
decreased mitochondrial metabolism. 
The mitochondrial deacetylase Sirt3 (Sirtuin 3) is critical in the 
regulation of metabolic and antioxidant functions which are 
associated with hypertension, and cardiovascular disease risk 
factors diminish Sirt3 level
SIRT 3 is a histone deacetylase that depends on NAD
. Mitochondrial dysfunction is associated 
with hypertension and it results in impaired energy production and 
deficient calcium homeostasis [39] and decreased activity of anti-
oxidant enzymes.  
+
There is a strong association between essential hypertension and 
the inflammatory process. Therefore, evaluation of inflammatory 
markers like C-reactive protein, adhesion molecules such as vascular 
cell adhesion molecule-1, intercellular adhesion molecule-1 and 
chemokines in can prove to be useful in determining therapeutic 
responses and clinical outcomes of hypertensive patients [43]. 
activity and 
displays crucial anti-oxidant properties. Augmented angiotensin-II 
levels also associated with the down-regulation of SIRT3 gene 
expression [40]. RAAS blockade seems to confer direct benefits by 
attenuating mitochondrial alterations. Oxidative stress provoke the 
release of pro-inflammatory mediators like Interleukin (IL)-1 and 
tumor necrosis factor (TNF)-α, which decrease the function of 
mitochondrial aldehyde dehydrogenase-2 [41]. Cardiolipin an 
important phospholipid vital for the balanced function of 
mitochondria is also reduced in hypertension [42]. 
Cancer 
The metabolic switch from aerobic glucose metabolism through the 
respiratory chain to anaerobic glycolysis is typical of cancer cells and 
was named the Warburg effect in honor of its discoverer. Warburg 
theory postulated that the driver of tumorigenesis is defective cellular 
respiration, which in turn is caused by defective mitochondrial 
functionand cancer can’t survive in an alkaline, oxygen rich environment 
but thrives in an acidic, low oxygen environment [44]. 
Mutations in different complexes of ETC are linked to various types 
of cancers (head and neck squamous cell carcionomas, colorectal 
cancers, oncocytoma, breast cancer etc). Dysfunctional mitochondria 
trigger retrograde signaling (mitochondria-to-nucleus) as a cellular 
adaptive response and has been reported in many pathological 
conditions. Mitochondrial retrograde signaling reprograms cells 
towards tumorigenesis, p53 gene has tumour suppressor activity 
and is present in chromosome 17. It prevents cell division of cells 
with damaged DNA. Damaged DNA could contain genetic changes 
that promote uncontrolled cell growth. p 53gene mutation is 
associated with 50% of human cancers including cancers of the 
bladder, breast, cervix, colon, lung, liver, prostrate, and skin [45]. 
Down syndrome  
Trisomy of chromosome 21 is a common disorder and is prevalent in 
1 in 700 newborns. In primary human lines of Down Syndrome 
foetal fibroblasts, TS21 is demonstrated to disturb the expression of 
genes involved in mitochondrial pathways, decrease oxygen 
consumption, ATP content and increase mt Ca2+load and ROS 
production.  
It has also been found that The impaired activity of the 
transcriptional co-activator PGC-1α/PPARGC1A and the hyper 
activation of the mammalian target of rapamycin (mTOR) kinase are 
emerging as underlying molecular causes of these mitochondrial 
alterations. indicating direct relationship between Down Syndrome 
and mitochondrial dysfunction. 
Therefore, it is likely that either stimulating the PGC-1α activity or 
inhibiting mTOR signaling could reverse mitochondrial dysfunction [46]  
Schizophrenia 
Dysfunctional mitochondria are highly detrimental for the normal 
functions of the brain. It is found that perturbation of mitochondrial 
network dynamics might lead to various nervous system disorders 
with inflammatory pathologies. Mitochondrial deficit, altered redox 
balance and chronic low-grade inflammation are evident in 
schizophrenia. Glutamate pathways and GABA receptors in striatum 
are vulnerable to oxidative stress and higher risk of neuronal death. 
Autism 
Mitochondrial dysfunction adversely influences high energy 
dependent neurodevelopment. Children with autism are more likely 
to have mitochondrial dysfunction, mtDNA over replication, and 
mtDNA deletions [47]. 
Epilepsy 
ATP is essential for normal electrical activities of neurons, synaptic 
transmission, neurotransmitter synthesis, calcium homoeostasis, 
redox signaling, ROS production and neuronal death. Dysfunction of 
mitochondria can render the brain more susceptible to epileptic 
seizures [48, 49]. Mitochondria can be considered as promising 
targets for neuroprotective strategies in epilepsy 
Muscle atrophy 
Oxidative stress is associated with age-related muscle loss 
(sarcopenia). Chronic oxidative stress due to loss of Sod1 gene 
exacerbates muscle atrophy during aging via mitochondrial 
dysfunction, activation of mitochondrial-mediated myonuclear 
apoptosis, and by altering neuromuscular innervation. Superoxide-
induced neuromuscular junction (NMJ) degeneration and 
mitochondrial dysfunction are one of the potential mechanisms that 
leads to sarcopenia in vivo [50]. 
Muscle wasting after extended periods of skeletal muscle inactivity 
is linked with mitochondrial dysfunction. Inactivity-induced 
alterations in skeletal muscle mitochondria phenotype and 
increased ROS emission, impaired Ca2+
Mitochondria as a therapeutic target 
handling, and release of 
mitochondria-specific proteolytic activators are established to 
promote fibre atrophy during prolonged periods of muscle inactivity 
[51]. 
Present therapeutic approach to treat mitochondrial diseases 
include non-pharmacological and pharmacological interventions. 
Nonpharmacological principally involve lifestyle intervention which 
include Aerobic exercises and calorie restriction. The 
Pharmacological intervention target Cofactors of OXPHOS for ATP 
production, Neutraceuticals,ROS scavengers and mitochondrial 
antioxidants,Inhibitors of the mtPTP (Mitochondrial Permeability 
and Transition Pore) and apoptosis, Enhancement of mitochondrial 
biogenesis and Mitochondrial Replacement Therapy (MRT) 
Lifestyle interventions 
Besides pharmacological agents, aerobic exercise (resistance exercise, 
endurance exercise) stimulates OXPHOS, mitochondrial biogenesis and 
glucose/lipid metabolism by increasing mitochondrial size, number and 
oxidative activity. Adequate calorie restriction (Ketogenic diet-low 
glucose, high ketones) bypasses glycolytic pathway, increases 
mitochondrial biogenesis, ATP production; reduces ROS production and 
insulin resistance. Environmental influences of diet and exercise can 
have a significant impact on mitochondrial function. Diet is known to 
affect the epigenetic regulation of human mitochondrial superoxide 
dismutase [52].  
Both overexertion and lack of physical activity can strain 
mitochondria, but exercise is one of the standard effective treatment 
modalities for PMD and SMD. Regular physical activity has beneficial 
actions on cardiovascular system. Aerobic exercise increases the 
production of nitric oxide, lowers the levels of superoxide and 
hydrogen peroxide and improves endogenous enzymatic anti-
oxidant systems and reduces systolic and diastolic blood pressure in 
hypertensive subjects, whereas isometric exercise affects only 
systolic blood pressure [53]. 
The catabolism associated with psychological stress causes a substantial 
change in mitochondrial function. In addition, acute and chronic 
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infections are among the most potent environmental forces exerting 
their effects on mitochondria via inflammatory processes [54]. 
CONCLUSION 
Mitochondria perform various vital functions in the body, including 
their ability to synthesise ATP. The dysfunction of mitochondria 
result in the energy depletion and accumulation of oxidants. In 
mitochondrial dysfunction the vital organs exclusevely depending on 
ATP for their function suffers most. The oxidative stress is 
associated with pathophysiology of various disorders especially 
involving neurons and cardiovascular system. Mitochondrial 
disorders are either Primary or secondary disorders. Primary 
mitochondrial disease (PMD) result from a mutation affecting 
oxidative phosphorylation (OXPHOS) genes. While Secondary 
mitochondrial dysfunction (SMD) does not involve OXPHOS but is 
because of mutations in non OXPHOS genes. Secondary 
mitochondrial dysfunction (SMD) can also be acquired secondary to 
adverse factors those cause oxidative stress. Neurodegenerative 
disorders, Huntington’s disease, cardiovascular disease (CVD), 
epilepsy, aging, metabolic syndrome, diabetes, autism, muscular 
atrophy, lou gehrig’s disease, neoplasia, down syndrome are few 
instances where mitochondrial dysfunction is the basic cause in 
pathogenesis.  
All this highlights the role of mitochondria and makes it a new 
therapeutic target in managing these disorders. The present review 
has discussed the secondary mitochondrial dysfunctional disorders 
and briefly approach to tackle it. Lifestyle intervention (healthy diet 
and regular exercise), pharmaceutical strategies and treating 
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